Semaglutide research: the mechanism, the pivotal trials, and how it compares.

Before the details

Semaglutide research breaks into a few clean parts. It starts with a mechanism: the drug copies a natural gut hormone (GLP-1) that tells the body to release insulin after eating, slows how fast the stomach empties, and signals the brain that you are full. From there the evidence follows the body — weight, blood sugar, the heart, the kidneys, the liver.

The weight trials (the STEP program) are the headline for this site: about 15% average weight loss over roughly 16 months ^[1]. The heart trials (SUSTAIN-6 and SELECT) showed fewer heart attacks and strokes ^[2][3]. The kidney trial (FLOW) showed slower kidney decline ^[6]. A head-to-head trial against a newer dual-hormone drug, tirzepatide, gives an honest comparison ^[7]. Every number below is tied to the study that produced it. None of it is dosing advice.

How does semaglutide work

Semaglutide is a long-acting agonist (activator) of the GLP-1 receptor — the docking site for glucagon-like peptide-1, an incretin hormone the gut releases after a meal. Native GLP-1 lasts only about two minutes because an enzyme called DPP-4 (dipeptidyl peptidase-4) breaks it down almost immediately. Semaglutide is engineered around that: a single building-block substitution at position 8 blocks DPP-4 cleavage, and a fatty-acid side chain binds tightly and reversibly to albumin (a carrier protein in blood), which slows clearance. Together these extend its life in the body from minutes to roughly a week.

When it activates GLP-1 receptors, semaglutide increases glucose-dependent insulin secretion from the pancreas (insulin rises only when blood sugar is high, which limits the risk of lows), suppresses inappropriate glucagon release, and slows gastric emptying. Its weight effect, though, is mainly in the brain. In rodent studies it reached the brainstem and the hypothalamic arcuate nucleus — appetite-control regions — activating satiety-promoting POMC/CART neurons and quieting hunger-driving NPY/AgRP neurons, which cut food intake and shifted food preference without lowering energy expenditure ^[4]. A pharmaceutical-sciences review summarizes how that structure-based long half-life supports once-weekly or once-daily dosing across indications ^[11].

The weight-management evidence: the STEP program

The weight evidence is anchored by STEP 1: in 1,961 adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% with placebo ^[1]. The companion STEP 2 report extended the program to adults with type 2 diabetes ^[10]. Durability was shown in STEP 5, where two years of treatment produced sustained, clinically meaningful weight loss versus placebo ^[8].

The STEP 4 randomized-withdrawal design isolated the role of continued treatment: from week 20 to 68, participants who stayed on semaglutide lost a further 7.9% of body weight, while those switched to placebo regained 6.9% ^[9]. Adolescents were studied in STEP TEENS, where once-weekly 2.4 mg produced a significantly greater reduction in BMI than placebo over 68 weeks ^[23]. The practical limit of the approach is regain after stopping, quantified in the STEP 1 extension at a mean of roughly 11.6 percentage points within a year ^[17].

The cardiovascular, kidney and liver trials

Cardiovascular outcomes came first in type 2 diabetes. In SUSTAIN-6 (n=3,297 at high cardiovascular risk), once-weekly semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (HR 0.74; 95% CI 0.58-0.95), while diabetic-retinopathy complications were more frequent (HR 1.76; 95% CI 1.11-2.78) ^[2]. The benefit was then established outside diabetes: in SELECT (n=17,604) of adults with established cardiovascular disease and overweight or obesity, once-weekly 2.4 mg cut major adverse cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) ^[3].

Kidney outcomes were established in FLOW (n=3,533) in type 2 diabetes with chronic kidney disease: once-weekly 1.0 mg reduced major kidney-disease events by 24% (HR 0.76; 95% CI 0.66-0.88) ^[6]. Liver disease followed in the 2025 ESSENCE phase-3 trial in biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis, an inflammatory fatty-liver disease), where once-weekly 2.4 mg achieved resolution of steatohepatitis without worsening fibrosis in 62.9% of patients versus 34.3% with placebo ^[12].

Semaglutide vs tirzepatide

The most-asked comparison is semaglutide vs tirzepatide, and there is now a direct answer. In the SURMOUNT-5 head-to-head trial (n=751) in adults with obesity, tirzepatide — a dual agonist that activates two gut-hormone receptors (GIP and GLP-1) rather than one — produced greater mean weight loss than semaglutide at 72 weeks: -20.2% versus -13.7%, a roughly 6.5-percentage-point advantage that was statistically significant (P<0.001) ^[7].

The honest reading is that both are highly effective and that, in this trial, the dual agonist produced more weight loss. SURMOUNT-5 measured weight, not cardiovascular or kidney outcomes, where semaglutide carries the larger dedicated-trial record (SELECT, FLOW) ^[3][6]. A head-to-head on weight is one axis of comparison, not the whole picture. This site uses generic compound names only and does not rank brands.

Interpreting the record

Read together, the semaglutide research describes a GLP-1 receptor agonist with large, reproducible weight effects, dedicated outcome trials in the heart and kidney, and a newer liver indication — set against a tolerability profile led by transient gastrointestinal effects and a small number of monitored safety signals. A dedicated safety review frames the overall risk-benefit profile as favorable, with the dominant adverse effects mild-to-moderate and transient and the more serious signals (pancreatic and thyroid cancer) unconfirmed given low incidence ^[5]. The strongest, most consistent finding for the weight-management lens is the magnitude and durability of weight loss while on treatment — and the equally consistent regain after it stops ^[9][17]. The full citation list is on the Semaglutide references page.